

REGENERON PHARMACEUTICALS INC
 Form 4
 February 08, 2012

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
GOLDBERG MURRAY A

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN, NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS INC [REGN]

3. Date of Earliest Transaction (Month/Day/Year)
 02/06/2012

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)
 Director 10% Owner
 Officer (give title below) Other (specify below)
 SVP Finance and Admin CFO Trea

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
			Code	V	Amount	Price	
Common Stock	02/06/2012		M ⁽¹⁾		18,750	A \$ 16.8	105,861 D
Common Stock	02/06/2012		F ⁽¹⁾		3,206	D \$ 98.23	102,655 D
Common Stock	02/06/2012		F ⁽¹⁾		7,160	D \$ 98.23	95,495 D
Common Stock	02/06/2012		M ⁽¹⁾		9,375	A \$ 21.25	104,870 D
	02/06/2012		F ⁽¹⁾		2,027	D \$ 98.23	102,843 D

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock									
Common Stock	02/06/2012		F ⁽¹⁾	3,384	D	\$ 98.23	99,459		D
Common Stock	02/06/2012		M ⁽¹⁾	12,788	A	\$ 24.86	112,247		D
Common Stock	02/06/2012		F ⁽¹⁾	3,236	D	\$ 98.23	109,011		D
Common Stock	02/06/2012		F ⁽¹⁾	4,400	D	\$ 98.23	104,611		D
Common Stock	02/07/2012		S ⁽¹⁾	13,265	D	\$ <u>99.67</u> ⁽²⁾	91,346		D
Common Stock	02/07/2012		S ⁽¹⁾	3,735	D	\$ <u>100.42</u> ⁽³⁾	87,611		D
Common Stock	02/07/2012		S ⁽¹⁾	500	D	\$ <u>101.35</u> ⁽⁴⁾	87,111		D
Common Stock							5,416	I	By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)	8. Date Exercisable	9. Expiration Date	10. Title	11. Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	\$ 16.8	02/06/2012		M ⁽¹⁾	18,750	<u>(5)</u>	Common Stock		12/17/2018		18,750
Non-Qualified Stock Option	\$ 21.25	02/06/2012		M ⁽¹⁾	9,375	<u>(5)</u>	Common Stock		12/18/2019		9,375

